| 冯焕荣1 李青1 王海琳2△.新型靶向治疗药物拉帕替尼的研究进展[J].,2012,12(4):746-747 |
| 新型靶向治疗药物拉帕替尼的研究进展 |
| The Research Progress of New Targeted Therapy Drugs Lpatinib |
| |
| DOI： |
| 中文关键词: 拉帕替尼（Lapatinib）；HER2/EGFR 乳腺癌；头颈部鳞癌（HNSCC）；卵巢癌 |
| 英文关键词: Lapatinib HER2/EGFR Breast cancer Head and neck squamous cell carcinoma（HNSCC） Ovarian cancer |
| 基金项目:湖北省自然科学基金（2010CDB10702） |
|
| 摘要点击次数: 833 |
| 全文下载次数: 2721 |
| 中文摘要: |
| 拉帕替尼(lapatinib)是一种口服的、小分子可逆性EGFR 和HER2 双受体阻断剂。临床研究表明对HER2 表达阳性的乳腺癌
是有效的。近年来关于拉帕替尼在其他肿瘤的研究越来越多，拉帕替尼有望成为一种潜在、多肿瘤的靶向治疗药物。本文对拉帕
替尼的作用机制、临床研究、药理特性及临床应用等做一综述。 |
| 英文摘要: |
| Lapatinib is an oral small molecule dual tyrosine kinase inhibitor against epidermal growth factor receptor (EGFR)
and HER-2/neu. Clinical trials showed that lapatinib is effective for patients with HER2-positive breast cancer. In recent years, the
researches of lapatinib in other cancers are rmore and more. lapatinib is expected to become a potential, multi-tumors targeting therapy
drugs. In this review, we summarize the interaction mechanisms, clinical studies, pharmacologic characteristics and clinical application of
lapatinib. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
